Azenta Inc (AZTA)vsMedline Inc. Class A Common Stock (MDLN)
AZTA
Azenta Inc
$34.20
+0.32%
HEALTHCARE · Cap: $1.48B
MDLN
Medline Inc. Class A Common Stock
$34.66
+1.05%
HEALTHCARE · Cap: $46.15B
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 4778% more annual revenue ($29.94B vs $613.81M). MDLN leads profitability with a 2.3% profit margin vs -20.0%. AZTA earns a higher WallStSmart Score of 57/100 (C).
AZTA
Buy57
out of 100
Grade: C
MDLN
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+35.0%
Fair Value
$46.86
Current Price
$34.20
$12.66 discount
Intrinsic value data unavailable for MDLN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 8778.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Earnings expanding 262.0% YoY
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
ROE of -11.5% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Distress zone — elevated risk
ROE of 6.0% — below average capital efficiency
2.3% margin — thin
Operating margin of 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZTA
The strongest argument for AZTA centers on Price/Book, EPS Growth, Debt/Equity. Revenue growth of 12.0% demonstrates continued momentum. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bull Case : MDLN
The strongest argument for MDLN centers on EPS Growth, Price/Book. Revenue growth of 11.6% demonstrates continued momentum.
Bear Case : AZTA
The primary concerns for AZTA are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : MDLN
The primary concerns for MDLN are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 42.9x leaves little room for execution misses. Thin 2.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZTA profiles as a turnaround stock while MDLN is a value play — different risk/reward profiles.
AZTA is growing revenue faster at 12.0% — sustainability is the question.
MDLN generates stronger free cash flow (604M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZTA scores higher overall (57/100 vs 52/100) and 12.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Azenta Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Azenta Inc. is a premier provider of sample management solutions and life science tools, dedicated to enhancing laboratory efficiencies within the biotechnology and pharmaceutical industries. The company excels in innovative automation and comprehensive biorepository services, facilitating faster drug discovery while ensuring adherence to stringent regulatory standards. With a forward-looking strategy that leverages advanced storage technologies and strategic partnerships, Azenta is uniquely positioned to seize growth opportunities in the expanding global life sciences market. Its commitment to pioneering scientific research through sophisticated innovations underscores its potential appeal to institutional investors seeking exposure in the dynamic life sciences sector.
Visit Website →Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?